More Imugene Ltd news
Imugene LtdASX: IMU

S&P DJI Announces September 2021 Quarterly Rebalance

Sep 3, 2021 at 7:31 AM EDT · Issued by Imugene Ltd

Filed with ASX · Sep 3, 2021 at 7:31 AM EDT · 4 pages · English

On 6ix: 6ix.com/news/sandp-dji-announces-september-2021-quarterly-rebalance-30

Imugene Ltd on 6ix

Story so far

  • S&P DJI Announces March 2021 Quarterly RebalanceMar 12, 2021

Earlier from Imugene

  • Imugene HER-Vaxx Phase 2 PFS Data and Flags Three New TrialsAug 31, 2021
  • Appendix 4E and Full Year Statutory AccountsAug 30, 2021
  • Phase 1 Clinical Trial Update of Immunotherapy PD1-VaxxAug 26, 2021
  • Response to ASX QueryAug 23, 2021
  • Research partnership with Celularity for solid tumorsAug 4, 2021

Later from Imugene

  • Imugene HER-Vaxx Immunotherapy Patent Granted in JapanSep 21, 2021
  • First patient dosed in Phase I clinical trial of CHECKvaccOct 20, 2021
  • Investor Presentation Imugene Eureka TherapeuticsOct 31, 2021
  • Clinical Trial Supply Agreement with Merck KGaA and PfizerNov 15, 2021
  • S&P DJI Announces December 2021 Quarterly RebalanceDec 3, 2021
All Imugene news releases↗

Follow Imugene into a list and get an email when it puts out news.

Follow Imugene
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer